4.1 Review

Chromatin, cancer and drug therapies

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.mrfmmm.2008.07.006

Keywords

Epigenetics; Chromatin; Cancer; DNA methylation inhibitors; HDAC inhibitors; Epigenetic therapy

Funding

  1. NIH [R01 CA83867]

Ask authors/readers for more resources

The structure and organization of chromatin have attracted a great deal of attention recently because of their implications for the field of epigenetics. DNA methylation and the post-translational modifications that occur on histones can specify transcriptional competency. During cancer development, tumor suppressor genes become silenced by DNA hypermethylation and chromatin modifiers no longer perform in their usual manner. Current epigenetic therapy has been able to take advantage of the reversibility of these epimutations. Progress has been made in the treatment of hematological malignancies and some solid tumors. As the knowledge of how chromatin regulates gene expression is enhanced, improvements in the treatment of cancer can be made. (c) 2008 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available